|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Delta9-tetrahydrocannabinol (9-THC) is an effective anti-emetic; however, other potential gastrointestinal therapeutic effects of
9-THC are less well-known. Here, we report a role of
9-THC in a vago-vagal reflex that can result in gastro-oesophageal reflux, that is, gastric distension-evoked lower oesophageal sphincter (LOS) relaxation. Oesophageal, LOS and gastric pressures were measured using a miniaturized, manometric assembly in decerebrate, unanaesthetized ferrets. Gastric distension (30 ml) evoked LOS relaxation (70 ± 8 % decrease from baseline).
9-THC administered systemically (0.2 mg kg-1, I.V.) or directly to the dorsal hindbrain surface (0.002 mg), significantly attenuated the nadir of the gastric distention-evoked LOS relaxation, and time to reach maximal response. Similar increases to maximal effect were observed after treatment with the cannabinoid receptor agonist WIN 55,212-2 (0.2 mg kg-1, I.V.). The effect of systemic
9-THC on gastric distention-evoked LOS relaxation was reversed by a selective cannabinoid1 (CB1) receptor antagonist, SR141617A (1 mg kg-1, I.V.). Since this reflex is vagally mediated, we used a CB1 receptor antiserum and immunocytochemistry to determine its distribution in ferret vagal circuitry. CB1 receptor staining was present in cell bodies within the area postrema, nucleus tractus solitarius (NTS) and nodose ganglion. Intense terminal-like staining was noted within the NTS and dorsal motor vagal nucleus (DMN). Neither nodose ganglionectomy nor vagotomy altered the CB1 receptor terminal-like staining in the dorsal vagal complex. Retrogradely labelled gastric- or LOS-projecting DMN neurones did not express CB1 receptors within their soma. Therefore, CB1 receptor staining in the NTS and DMN is not due to primary vagal afferents or preganglionic neurones. These novel findings suggest that
9-THC can modulate reflex LOS function and that the most likely site of action is via the CB1 receptor within the NTS. This effect of
9-THC may have implications in treatment of gastro-oesophageal reflux and other upper gut disorders.
This article has been cited by other articles:
![]() |
A A Izzo and M Camilleri Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects Gut, August 1, 2008; 57(8): 1140 - 1155. [Abstract] [Full Text] [PDF] |
||||
![]() |
R K Mittal and V Bhalla Oesophageal motor functions and its disorders Gut, October 1, 2004; 53(10): 1536 - 1542. [Full Text] [PDF] |
||||
![]() |
A. V. Derbenev, T. C. Stuart, and B. N. Smith Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve J. Physiol., September 15, 2004; 559(3): 923 - 938. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. K. MacNaughton, M. D. Van Sickle, C. M. Keenan, K. Cushing, K. Mackie, and K. A. Sharkey Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves Am J Physiol Gastrointest Liver Physiol, May 1, 2004; 286(5): G863 - G871. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Burdyga, S. Lal, A. Varro, R. Dimaline, D. G. Thompson, and G. J. Dockray Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin J. Neurosci., March 17, 2004; 24(11): 2708 - 2715. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |